BioSpace News Archive

Albany NY, United States: The global mechanical ventilators market is likely to expand at a CAGR of 12.8% during the forecast period of 2019 to 2027, notes a research report by Transparency Market Research.

Paragon 28, Inc. announced today the launch of its R3ACT™ Stabilization System, designed to be a simple solution that allows for multi-stage soft tissue healing following an acute or chronic syndesmotic injury to the ankle.

Biophytis SA announces it will present and discuss the results of Sarconeos development program in Sarcopenia at the 12th annual International Conference on Frailty and Sarcopenia Research to be held virtually and on site in Boston from April 20 to April 22, 2022.

GC corp. announced that it has signed a definitive agreement to acquire 100% of the shares of BioCentriq, Inc., a pioneering US-based contract development and manufacturing organization that designs and develops scalable cell and gene technologies.

Microviable Therapeutics SL, a preclinical stage biotechnology company developing orally administered biological drugs based on microbiota-derived products, announced 1.5 million euros seed funding from the private medical group Inmunomet Intolerancia y Disbiosis SL.

NTC Srl, R&D driven pharmaceutical company with headquarters in Italy announces the submission of the marketing authorisation application through the European Decentralised Procedure for its development product NTC015 for bowel preparation for colonoscopy.

BioAge Labs, Inc. announced that the first cohort has been dosed in a Phase 1b trial of BGE-105, a highly selective and potent small-molecule agonist of the apelin receptor APJ.

BeiGene announced the presentation of updated data analyses from the Phase 3 RATIONALE-309 trial of tislelizumab, a humanized anti-PD-1 monoclonal antibody, in combination with chemotherapy versus chemotherapy plus placebo as a first-line treatment for patients with recurrent or metastatic nasopharyngeal cancer, at the virtual American Society of Clinical Oncology Plenary Series on April 19, 2022.

Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, announced the comprehensive launch of the Axonics F15 across the United States.

Johnson & Johnson announced results for first-quarter 2022. “Our first quarter results demonstrate strong performance across the enterprise, despite macro-economic headwinds.